naotake Neurocrine Biosciences ( NASDAQ: NBIX ) CEO Kevin Gorman will step down from that position on Oct. 11 but remain on the company's board. Kyle Gano, currently chief business development and strategy officer, will succeed him and also join the board.
Gorman founded the company and has served as CEO since 2008. Gano joined Neurocrine ( NBIX ) 23 years ago. He became chief business development officer in 2011 and chief business development and strategy officer in 2020.
More on Neurocrine Biosciences Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data Neurocrine Q1 revenue beats Street, gets FDA okay for Ingrezza Sprinkle Neurocrine Biosciences Q1 2024 Earnings Preview Seeking Alpha’s Quant Rating on Neurocrine Biosciences.
